Real-world recurrence patterns and patient outcomes after 2 years of pembrolizumab immunotherapy in advanced non-small cell lung cancer.
Clinical Lung Cancer · 2026-11
DOI: 10.1016/j.cllc.2026.11.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-11. Verfasst von Laurine RIVARD und 8 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs), including pembrolizumab, have significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) without actionable oncogenic addiction. A minority of patients present a sustained response and can complete two years of pembrolizumab, but little is known about their outcomes and the factors predictive of recurrence after treatment discontinuation.
Methods
We conducted a retrospective study at the Comprehensive Cancer Center Léon Bérard (France) including consecutive patients with advanced NSCLC who received ≥20 months of pembrolizumab between 2017 and 2025. The primary endpoint was progression-free survival (PFS) from pembrolizumab discontinuation; secondary endpoints included overall survival (OS) and identification of prognostic factors for PFS with a multivariate Cox regression model.
Results
Among 199 screened patients, 95 met eligibility criteria. 59% had PD-L1≥50%. 28% had brain metastases at diagnostic. After >20 months of treatment, 40% achieved complete response and 56% partial response; among 83 patients who underwent FDG-PET-CT evaluation, 55% showed no significant FDG uptake. With a median follow-up of 31.4 months, median PFS was not reached, with a 24-month PFS rate of 76% (95% CI, 65%–84%). Median OS was not reached with a 24-month OS rate of 95% (95% CI, 87%–98%). In multivariate analysis, the absence of brain metastases at diagnosis was the only factor independently associated with a longer PFS (HR = 0.33, 95% CI 0.15–0.71, p = 0.005).
Conclusions
In our study, patients with advanced NSCLC who completed two years of pembrolizumab had 24-month PFS and OS rates at 76% and 95%, respectively. Considering the limitations due to a small sample size, brain metastases at diagnosis was the only independent factor associated with PFS after treatment discontinuation.
Zitieren
APA
RIVARD, L., CROPET, C., AVRILLON, V., MASTROIANNI, B., DECROISETTE, C., GILLE, R., WESPISER, M., SWALDUZ, A., & PEROL, M. (2026). Real-world recurrence patterns and patient outcomes after 2 years of pembrolizumab immunotherapy in advanced non-small cell lung cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.11.008
Vancouver
RIVARD L, CROPET C, AVRILLON V, MASTROIANNI B, DECROISETTE C, GILLE R, et al. Real-world recurrence patterns and patient outcomes after 2 years of pembrolizumab immunotherapy in advanced non-small cell lung cancer. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.11.008
BibTeX
@article{RIVARD2026,
author = {RIVARD, Laurine and CROPET, Claire and AVRILLON, Virginie and MASTROIANNI, Bénédicte and DECROISETTE, Chantal and GILLE, Romane and WESPISER, Mylène and SWALDUZ, Aurélie and PEROL, Maurice},
title = {Real-world recurrence patterns and patient outcomes after 2 years of pembrolizumab immunotherapy in advanced non-small cell lung cancer},
journal = {Clinical Lung Cancer},
year = {2026},
doi = {10.1016/j.cllc.2026.11.008}
}
EUVIMED